Market open
Agios/$AGIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Agios
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Ticker
$AGIO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
487
Website
Agios Metrics
BasicAdvanced
$1.8B
2.75
$11.64
0.88
-
Price and volume
Market cap
$1.8B
Beta
0.88
52-week high
$59.29
52-week low
$27.14
Average daily volume
696K
Financial strength
Current ratio
11.898
Quick ratio
11.063
Long term debt to equity
2.609
Total debt to equity
3.698
Management effectiveness
Return on assets (TTM)
-20.47%
Return on equity (TTM)
57.29%
Valuation
Price to earnings (TTM)
2.747
Price to revenue (TTM)
49.775
Price to book
1.19
Price to tangible book (TTM)
1.19
Price to free cash flow (TTM)
-4.64
Growth
Revenue change (TTM)
36.07%
Earnings per share change (TTM)
-283.89%
3-year earnings per share growth (CAGR)
-24.03%
What the Analysts think about Agios
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Agios stock.
Agios Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Agios Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Agios News
AllArticlesVideos
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer
GlobeNewsWire·1 week ago
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025
GlobeNewsWire·3 weeks ago
Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript
Seeking Alpha·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Agios stock?
Agios (AGIO) has a market cap of $1.8B as of March 13, 2025.
What is the P/E ratio for Agios stock?
The price to earnings (P/E) ratio for Agios (AGIO) stock is 2.75 as of March 13, 2025.
Does Agios stock pay dividends?
No, Agios (AGIO) stock does not pay dividends to its shareholders as of March 13, 2025.
When is the next Agios dividend payment date?
Agios (AGIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Agios?
Agios (AGIO) has a beta rating of 0.88. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.